NEWS
Press Releases
- Feb 21 2012 Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
- Oct 21 2011 Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response
- Mar 09 2011 Xencor’s Fc Engineered Antibody Suppresses Autoimmunity in Preclinical Systemic Lupus Erythematosus Models; Data Published in Journal of Immunology
- Jan 06 2011 Amgen And Xencor Enter Option Deal To Co-develop Xencor’s Novel Antibody For Autoimmune Diseases
- Dec 02 2010 Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia
- Oct 12 2010 Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement
- Jun 28 2010 MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
- Feb 09 2010 Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer
- Jan 19 2010 Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience
- Dec 16 2009 Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement
- Dec 07 2009 Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board
- Nov 30 2009 Xencor Licenses Antibody Optimization Technology
- Jun 29 2009 Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board
- Jun 01 2009 Xencor Presents Preliminary Phase 1 Data on XmAb®2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting
- May 15 2009 Xencor to Present Phase 1 Data on XmAb®2513 Antibody for Lymphomas at the American Society of Clinical Oncology Annual Meeting
- Mar 23 2009 Xencor Licenses Xtend™ Antibody Half-life Prolongation Platform to Merck & Co., Inc.
- Mar 02 2009 Xencor and Pfizer enter into Antibody Technology Licensing Agreement
- Feb 23 2009 Xencor and CSL Limited Establish Antibody Optimization Collaboration
- Dec 09 2008 Xencor Presents Data from Pre-clinical Studies of its Anti-CD19 and Anti-CD40 Antibodies at the 50th Annual Meeting of the American Society of Hematology
- Dec 02 2008 Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference
- Jun 01 2008 Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO
- Apr 15 2008 Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR
- Apr 09 2008 Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings
- Mar 19 2008 Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors
- Feb 11 2008 Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma
- Feb 07 2008 Human Genome Sciences And Xencor Announce Antibody Collaboration
- Jan 09 2008 Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology
- Dec 10 2007 Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting
- Dec 07 2007 Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease
- Oct 24 2007 Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer
- Oct 24 2007 Xencor Expands Series E Financing to $60 Million
- Sep 20 2007 Xencor Selects Antibody Development Candidates
- Jul 23 2007 Xencor Data Published in Journal of Immunology Demonstrate Selectivity of New Class of Inhibitors for Inflammatory Disease
- Feb 13 2007 Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
- Oct 19 2006 Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures
- Sep 11 2006 Xencor’s XmAb™ Technology Wins Wall Street Journal 2006 Technology Innovation Award
- Jul 11 2006 Xencor Completes $6 Million Bridge Financing with Novo Nordisk and Existing Investors
- Mar 07 2006 Data Published in PNAS Show Engineering the Fc Region of Antibodies Makes Them More Toxic to Cancer Cells
- Feb 14 2006 Xencor Licenses Immunofilter™ Technology to Centocor Research and Development, Inc.
- Jan 18 2006 Lilly Licenses Xencor’s Immunofilter™ Technology
- Jan 04 2006 Xencor and Roche Extend XmAb™ Antibody Therapeutics Collaboration
- Dec 07 2005 MedImmune Licenses Xencor’s XmAb™ Technology To Create Antibody Therapeutics Against Select Tumor Targets; Fifth XmAb™ Deal For Xencor In The Last Year
- Oct 18 2005 Xencor Gives Panel Presentation and Company Update at BIO InvestorForum; Announces Recent Close of $20 Million in Financing
- Jul 18 2005 Xencor, Inc. Signs Collaboration with Centocor, Inc. to Improve Antibodies
- Jun 21 2005 FierceBiotech Honors Xencor as One of the
- Apr 13 2005 Xencor Licenses Protein Variants to Lilly
- Jan 10 2005 Xencor and Chugai Initiate Partnership for Optimized Antibodies
- Dec 01 2004 Xencor and Genentech to Collaborate to Develop Next-Generation Antibody Therapeutics
- Feb 18 2004 Xencor Announces Protein Optimization Collaboration with Lilly
- Jan 28 2004 Xencor Determines Structure Of Baff, A Key Autoimmune Disease Target
- Jan 12 2004 Xencor and Protein Design Labs Initiate Partnership for Optimized Antibodies
- Dec 09 2003 Xencor Announces Bassil Dahiyat As Its New Chief Scientific Officer
- Dec 09 2003 Xencor Announces Harry Stylli As Its New Chief Executive Officer
- Sep 25 2003 Xencor Designs Novel TNF Alpha Inhibitors To Treat Inflammatory Disease
- Sep 24 2003 Xencor Granted Patent on Optimized Pharmaceutical Protein
- Sep 23 2003 Chromos and Xencor announce agreement for use of the ACE System to produce biologics.
- Sep 23 2003 Bassil Dahiyat Named One of the World’s Top Young Innovators
- Oct 09 2002 Xencor Receives Advanced Technology Program Grant For Safer Protein Therapeutics
- Jun 17 2002 Xencor Reaches Research Milestone
- Jun 04 2002 Enhancing The Therapeutic Utility of Biopharmaceuticals: The Next Frontier
- May 29 2002 Xencor Optimizes Key Pharmaceutical Proteins
- Apr 18 2002 Chemical Genomics – CALBIOsummit 2002 April 21,22,23
- Mar 11 2002 Xencor Licenses Patent For Chemical Genomics Technology Profiling Biological And Pharmacological Interactions
- Feb 20 2002 Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products
- Jan 03 2002 Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement
- Oct 09 2001 Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs
- Aug 06 2001 Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products
- Jul 19 2001 Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts
- Jun 19 2001 Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins
- Jun 14 1999 Xencor Closes $12.3 Million in Financing
- Jan 05 1999 Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting
- Nov 30 1998 Xencor Licenses Caltech Technology